Hepatitis B Immune Globulin I.V. Approval Could Rely On Open-Label Studies, Historical Controls – FDA

The agency's briefing materials for the March 18 meeting of the Blood Products Advisory Committee note that prospective trials could be difficult because HBIGIV is currently used off-label in combination with antiviral drugs.